

VEGF165

Catalog # PVGS1032

Product Information

Primary Accession P15692-4
Species Human

Sequence Ala27-Arg191

Purity > 95% as analyzed by SDS-PAGE

Endotoxin Level

Biological Activity ED₅₀ of 1.0-5.0 ng/ml, measured by the dose-dependent stimulation of the

proliferation of HUVEC cells, corresponding to a specific activity of 2.0 ×

 10^5 -1.0 × 10^6 units/mg.

Expression System P. pastoris

Formulation Lyophilized after extensive dialysis against 25 mM HEPES, 150 mM NaCl, pH

7.0.

Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to

bring the contents to the bottom. Reconstitute the lyophilized powder in

 ddH_2O up to 100 $\square g/ml$.

Storage & Stability Upon receiving, this product remains stable for up to 6 months at lower than

-70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw

cycles.

Additional Information

Target Background

Vascular Endothelial Growth Factor (VEGF) is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, Vascular Endothelial Growth Factor (VEGF) plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates Vascular Endothelial Growth Factor (VEGF) in the induction of tumor metastasis and intra-ocular neovascular syndromes. Vascular Endothelial Growth Factor (VEGF) signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product.

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.